Abstract
Five men with advanced breast cancer were treated with aminoglutethimide (AG) plus replacement dose hydrocortisone. None of the 4 patients with intact testes responded, although 3 did so subsequently to tamoxifen. The previously orchidectomized patient responded to aminoglutethimide for 14 months. Oestrone and oestradiol were suppressed by AG in all patients, but not to the levels achieved by orchidectomy. AG produced substantial further oestrogen suppression in the orchidectomized patient and should only be used after orchidectomy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Harris, A., Dowsett, M., Stuart-Harris, R. et al. Role of aminoglutethimide in male breast cancer. Br J Cancer 54, 657–660 (1987). https://doi.org/10.1038/bjc.1986.223
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.223
This article is cited by
-
Aromatase inhibitors with or without luteinizing hormone–releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature
Breast Cancer (2016)
-
Male breast carcinoma: radiotherapy contributed to favorable local control in two cases and related literature review
European Journal of Medical Research (2015)
-
Male breast cancer: a gender issue
Nature Clinical Practice Oncology (2006)
-
Male breast cancer
Current Treatment Options in Oncology (2003)